Amylyx Pharmaceuticals, Inc.
AMLX
$8.98
$0.556.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -249.00K | -1.27M | 87.37M | 196.49M | 298.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -249.00K | -1.27M | 87.37M | 196.49M | 298.76M |
| Cost of Revenue | 94.27M | 97.82M | 228.72M | 296.30M | 273.31M |
| Gross Profit | -94.52M | -99.09M | -141.35M | -99.82M | 25.45M |
| SG&A Expenses | 66.25M | 72.26M | 114.33M | 149.48M | 180.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.73M | 206.28M | 379.25M | 445.78M | 453.67M |
| Operating Income | -196.98M | -207.55M | -291.88M | -249.29M | -154.91M |
| Income Before Tax | -188.24M | -219.49M | -302.14M | -257.48M | -162.36M |
| Income Tax Expenses | -635.00K | -635.00K | -393.00K | 1.99M | 3.51M |
| Earnings from Continuing Operations | -187.60 | -218.86 | -301.74 | -259.47 | -165.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.60M | -218.86M | -301.74M | -259.47M | -165.87M |
| EBIT | -196.98M | -207.55M | -291.88M | -249.29M | -154.91M |
| EBITDA | -196.30M | -206.81M | -290.98M | -248.25M | -153.79M |
| EPS Basic | -2.50 | -3.10 | -4.43 | -3.82 | -2.44 |
| Normalized Basic EPS | -1.66 | -1.82 | -2.66 | -2.25 | -1.37 |
| EPS Diluted | -2.50 | -3.11 | -4.44 | -3.82 | -2.45 |
| Normalized Diluted EPS | -1.66 | -1.82 | -2.66 | -2.25 | -1.38 |
| Average Basic Shares Outstanding | 311.52M | 290.41M | 272.56M | 271.39M | 270.71M |
| Average Diluted Shares Outstanding | 311.52M | 290.41M | 272.56M | 273.17M | 274.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |